EGRX — Eagle Pharmaceuticals Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual cashflow statement for Eagle Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2018 December 31st	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	31.9	14.3	12	-8.63	35.6
Depreciation
Amortisation
Deferred Taxes
Non-Cash Items	27.2	22.5	34.7	27.2	27.8
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-7.89	14.4	0.816	9.54	-16.4
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Cash from Operating Activities	52.4	56	49.5	28.2	50.7
Capital Expenditures	-0.133	-0.777	-0.747	-0.323	-0.178
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	0	—	-17.5	-5	-86.7
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities	-0.133	-0.777	-18.2	-5.32	-86.8
Financing Cash Flow Items	-19.9	-0.524	-1.52	-1.58	-2.72
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-88.1	-24.2	-37.9	-28.4	-6.21
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-35.9	31	-6.62	-5.5	-42.3